Developer docs
API playgroundTry for free, no card

Search company profiles

Viramal

Full company profile

uuid000ene8

Namestring
Viramal
Legal namestring
Viramal Limited
Websiteurl
viramal.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Viramal is a UK-based specialty pharmaceutical company founded in April 2013 by Oliver Bates and Dr. Finn Larsen, with a wholly-owned subsidiary in Sweden supporting development operations. The company is focused exclusively on women's sexual and reproductive health therapeutics, targeting conditions including endometriosis, Female Androgen Deficiency Syndrome (FADS), chronic period pain, menopause, vaginal atrophy, and fertility challenges that the company describes as poorly served by existing drugs.

The company develops its products on a proprietary drug delivery platform called Fem Med Tech, which uses patented skin reservoir technology and a unique vaginal delivery platform to deliver active pharmaceutical ingredients transdermally or vaginally through cream formulations. The pipeline includes VML-0501 (a trans-vaginally delivered endometriosis candidate positioned as the first product to reach the pelvic cavity and preserve fertility), the ELEGANT (TM) portfolio of seven OTC female sexual health products planned for first US launch, menopausal hormone therapy creams, female and male testosterone replacement therapies, vaginal microbiome products, and earlier-stage programmes in vaginal cannabinoids and transdermal iron supplementation.

Viramal's intended revenue model is dual-track: prescription pharmaceutical products distributed through healthcare providers (targeting enterprise/clinical channels globally) and over-the-counter products sold directly to consumers, with the ELEGANT portfolio as the first OTC launch in the United States. Pricing has not been publicly disclosed and the company has not reported commercial revenue; its only disclosed financial relationship is a board observer seat held by METIS Family Office A/S / Investeringsselskabet MFO Private Equity A/S, with the DPTI Fund also holding a board seat. The company employs 11-50 staff and is privately held.

Short descriptiontext

Viramal is a UK-based specialty pharmaceutical company developing women's health therapeutics via its proprietary Fem Med Tech transdermal/vaginal cream platform, with a pipeline spanning endometriosis (VML-0501), OTC sexual health (ELEGANT), menopausal hormone therapy, and testosterone replacement products.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
women's health therapeutics, transdermal drug delivery, endometriosis treatment, hormone replacement therapy, vaginal health products
Industry4 codes
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIADAJ
Women’s Health (OTC Gynecologic)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYCRABAIAJ
Menstrual Pain Relief & Period Care Supplements
SECONDARYCRABAIAK
Fertility & Ovulation Products (OTC)
NAICS code1 code
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Women's Health Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Prescription Pharmaceutical Products
TypeOthers
Description

Prescription treatments developed for endometriosis, menopausal hormone therapy, and other women's health conditions. Products are in various stages of clinical development including VML-0501 for endometriosis.

viramal.com
2Over-the-Counter (OTC) Products
TypeOthers
Description

The ELEGANT (TM) Portfolio will be Viramal's first OTC product launching in the United States, targeting female sexual health and vaginal microbiome balance.

viramal.com
3Transdermal Hormone Therapies
TypeOthers
Description

Low-dose female hormone therapies delivered transdermally for systemic benefit and vaginally for localised symptoms, expected to demonstrate improved bioavailability.

viramal.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1ELEGANT (TM) Portfolio
Description

A pioneering range of female sexual health products including vaginal moisturiser targeting vaginal infection and microbiome balance; the first OTC product planned for US launch.

viramal.com
+1 more record
Core offering1 text field

Viramal is a specialty pharmaceutical company that develops prescription and over-the-counter treatments for women's sexual and reproductive health conditions, including endometriosis, menopause, female sexual health, fertility, and vaginal microbiome disorders. Products are formulated using the proprietary Fem Med Tech platform, which delivers active pharmaceutical ingredients through transdermal and vaginal cream formulations designed to increase potency, enable targeted tissue delivery, and minimise systemic side effects. The portfolio spans both clinical-stage prescription drug candidates and OTC consumer products such as the ELEGANT (TM) line.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • First treatment to preserve hormone balance and the ability to conceive for endometriosis patients
+5 more records
Product overview1 text field

Viramal is a specialist UK-based pharmaceutical company with a subsidiary in Sweden developing a portfolio of transformative healthcare products for women. The company's Fem Med Tech platform powers multiple product candidates spanning both prescription and over-the-counter treatments: VML-0501 for endometriosis (in clinical trials), the ELEGANT (TM) over-the-counter vaginal health portfolio including an Elegant Vaginal Moisturiser (registration in process), menopausal hormone therapy creams, female and male testosterone replacement therapies, vaginal microbiome products for conception preparation, and earlier-stage programmes in vaginal cannabinoids and iron supplementation. Products are delivered via proprietary transdermal or vaginal cream formulations.

Product and service8 records
1VML-0501
CategoryPrescription drug candidate
Description

Trans-vaginally delivered prescription drug candidate for endometriosis, positioned as the first treatment to preserve hormone balance and fertility ability, target pelvic cavity tissue via vaginal administration, rejuvenate ovarian tissue, and improve the telomere pathway in women with poor reproductive outcomes.

2ELEGANT (TM) Portfolio
CategoryOver-the-counter product line
Description

Pioneering OTC product range of seven female sexual health products, including an Elegant Vaginal Moisturiser that treats vaginal atrophy through microbiome balancing; aimed at alleviating vaginal discharge, tackling vaginal infection without antibiotics via anti-adhesion strategies, and promoting optimal vaginal health. First OTC product planned for US launch.

3Menopausal Hormone Therapy Products
CategoryPrescription drug candidate
Description

Range of low-dose female hormone therapies for hormone replacement treatment, delivered transdermally for systemic benefit and vaginally for localised symptoms. Formulated as an easy-to-use cosmetic-grade cream for daily use supporting healthier ageing.

4Female Testosterone Replacement Therapy
CategoryPrescription drug candidate
Description

Patented female testosterone product delivered as a regular daily dose to combat Female Androgen Deficiency Syndrome (FADS), characterised by fatigue, disturbed sleep, low energy, motivation and self-esteem, and lack of sexual libido. Positioned as the first registered female testosterone product.

5Male Testosterone Replacement Therapy
CategoryPrescription drug candidate
Description

Patient-acceptable transdermal testosterone cream suitable for use in chronic conditions, designed to contribute to the male hormone therapy market.

6Vaginal Microbiome Products
CategoryPrescription drug candidate
Description

Products that help create and maintain a healthy vaginal environment by supporting a pH-balanced microbiome essential for a woman's sexual and reproductive lifecycle, particularly targeted at women preparing to conceive and maintain healthy pregnancies.

7Vaginal Cannabinoids
CategoryResearch and development
Description

Research-stage therapies for chronic pelvic inflammatory diseases leveraging the high density of cannabinoid receptors in female pelvic organs, indicating strong propensity for cannabis absorption, treatment and efficacy.

8Iron Supplementation
CategoryPrescription drug candidate
Description

Transdermal or buccal iron therapies for Iron Deficiency Anemia (IDA), offering easy iron absorption and avoidance of gastrointestinal issues that plague existing oral iron supplementation.

Partnership1 partner
Strategic tierCoreTypeOthers
Description

Viramal acquired Bigel, an established company, to develop their pioneering product portfolio of women's health therapies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty pharmaceutical company exclusively dedicated to women's health, with portfolio spanning menopause, contraception, and reproductive medicine. Closely comparable as a women's health-only specialty pharma with similar therapeutic focus areas to Viramal's pipeline.

TypeDirect peer
Description

Women's health commercial-stage biopharmaceutical company with Phexxi vaginal gel for contraception and ongoing development in sexual health. Comparable focus on vaginal delivery formats and women's sexual/reproductive health commercialization.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing therapies for women's reproductive health, with lead asset in preterm labor and pipeline in endometriosis. Comparable as a small women's health-focused development company, though currently facing significant financial distress.

TypeBroad incumbent
Description

Global pharma with substantial women's health franchise including Mirena IUD, Yaz/Yasmin oral contraceptives, and hormone therapy products. Major incumbent with overlapping menopause, contraception, and reproductive health offerings and significant commercial scale.

TypeDirect peer
Description

Specialty pharmaceutical company focused exclusively on women's health, with marketed products in menopause hormone therapy and vaginal health. Direct overlap with Viramal's prescription and OTC women's health strategy, including similar focus on differentiated hormone delivery and vaginal health.

TypeBroad incumbent
Description

Global women's health-focused pharmaceutical company spun off from Merck in 2021, with established portfolio in contraception, fertility, menopause, and biosimilars. Broad incumbent with overlapping therapeutic areas including hormone therapy and reproductive health, serving as both competitor and potential acquirer.

TypeDirect peer
Description

Women's health pharma company developing therapies for uterine fibroids, endometriosis, and advanced prostate cancer. Directly comparable as a women's health-focused development-stage pharma with competing endometriosis asset (relugolix combination therapy), and was acquired by Sumitomo Pharma.

TypeBroad incumbent
Description

Global pharmaceutical leader with major women's health franchise including Orilissa/Oriahnn for endometriosis and Lupron for reproductive conditions. Major incumbent competitor whose commercial infrastructure and payer relationships set the bar Viramal must clear to capture endometriosis market share.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company focused on women's health with pipeline in contraception, vaginal health, and menopause. Comparable in stage and therapeutic focus, though Daré emphasizes contraceptive innovation and vaginal ring delivery rather than transdermal creams.

TypeDirect peer
Description

Women's health pharmaceutical company with FDA-approved Twirla contraceptive patch and pipeline in additional women's health indications. Comparable as a small-cap women's health pharma developing differentiated delivery formats for reproductive-age women.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Viramal

Women's Health Pharmaceuticalsviramal.com

Viramal is a UK-based specialty pharmaceutical company developing women's health therapeutics via its proprietary Fem Med Tech transdermal/vaginal cream platform, with a pipeline spanning endometriosis (VML-0501), OTC sexual health (ELEGANT), menopausal hormone therapy, and testosterone replacement products.

What Viramal does

Viramal is a UK-based specialty pharmaceutical company founded in April 2013 by Oliver Bates and Dr. Finn Larsen, with a wholly-owned subsidiary in Sweden supporting development operations. The company is focused exclusively on women's sexual and reproductive health therapeutics, targeting conditions including endometriosis, Female Androgen Deficiency Syndrome (FADS), chronic period pain, menopause, vaginal atrophy, and fertility challenges that the company describes as poorly served by existing drugs.

The company develops its products on a proprietary drug delivery platform called Fem Med Tech, which uses patented skin reservoir technology and a unique vaginal delivery platform to deliver active pharmaceutical ingredients transdermally or vaginally through cream formulations. The pipeline includes VML-0501 (a trans-vaginally delivered endometriosis candidate positioned as the first product to reach the pelvic cavity and preserve fertility), the ELEGANT (TM) portfolio of seven OTC female sexual health products planned for first US launch, menopausal hormone therapy creams, female and male testosterone replacement therapies, vaginal microbiome products, and earlier-stage programmes in vaginal cannabinoids and transdermal iron supplementation.

Viramal's intended revenue model is dual-track: prescription pharmaceutical products distributed through healthcare providers (targeting enterprise/clinical channels globally) and over-the-counter products sold directly to consumers, with the ELEGANT portfolio as the first OTC launch in the United States. Pricing has not been publicly disclosed and the company has not reported commercial revenue; its only disclosed financial relationship is a board observer seat held by METIS Family Office A/S / Investeringsselskabet MFO Private Equity A/S, with the DPTI Fund also holding a board seat. The company employs 11-50 staff and is privately held.

Viramal firmographics

Firmographics
Name
Viramal
Legal name
Viramal Limited
Website
https://viramal.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Viramal is a UK-based specialty pharmaceutical company developing women's health therapeutics via its proprietary Fem Med Tech transdermal/vaginal cream platform, with a pipeline spanning endometriosis (VML-0501), OTC sexual health (ELEGANT), menopausal hormone therapy, and testosterone replacement products.
Ownership category
akta.pro rank

Viramal industry classification

Industry
Product category
Women's Health Pharmaceuticals
NAICS
Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIADAJ
Women’s Health (OTC Gynecologic)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYCRABAIAJ
Menstrual Pain Relief & Period Care Supplements
SECONDARYCRABAIAK
Fertility & Ovulation Products (OTC)

Keywords

  • Women's health therapeutics
  • Transdermal drug delivery
  • Endometriosis treatment
  • Hormone replacement therapy
  • Vaginal health products

Where Viramal is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Viramal business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Prescription Pharmaceutical Products: Prescription treatments developed for endometriosis, menopausal hormone therapy, and other women's health conditions. Products are in various stages of clinical development including VML-0501 for endometriosis.
  2. Over-the-Counter (OTC) Products: The ELEGANT (TM) Portfolio will be Viramal's first OTC product launching in the United States, targeting female sexual health and vaginal microbiome balance.
  3. Transdermal Hormone Therapies: Low-dose female hormone therapies delivered transdermally for systemic benefit and vaginally for localised symptoms, expected to demonstrate improved bioavailability.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Viramal product offering

Product offering

Core offering

Viramal is a specialty pharmaceutical company that develops prescription and over-the-counter treatments for women's sexual and reproductive health conditions, including endometriosis, menopause, female sexual health, fertility, and vaginal microbiome disorders. Products are formulated using the proprietary Fem Med Tech platform, which delivers active pharmaceutical ingredients through transdermal and vaginal cream formulations designed to increase potency, enable targeted tissue delivery, and minimise systemic side effects. The portfolio spans both clinical-stage prescription drug candidates and OTC consumer products such as the ELEGANT (TM) line.

Product overview

Viramal is a specialist UK-based pharmaceutical company with a subsidiary in Sweden developing a portfolio of transformative healthcare products for women. The company's Fem Med Tech platform powers multiple product candidates spanning both prescription and over-the-counter treatments: VML-0501 for endometriosis (in clinical trials), the ELEGANT (TM) over-the-counter vaginal health portfolio including an Elegant Vaginal Moisturiser (registration in process), menopausal hormone therapy creams, female and male testosterone replacement therapies, vaginal microbiome products for conception preparation, and earlier-stage programmes in vaginal cannabinoids and iron supplementation. Products are delivered via proprietary transdermal or vaginal cream formulations.

Differentiator

Problem solved

Functional benefit

Brands

  • ELEGANT (TM) Portfolio: A pioneering range of female sexual health products including vaginal moisturiser targeting vaginal infection and microbiome balance; the first OTC product planned for US launch.
  • Fem Med Tech™

Products and services

  • VML-0501 Trans-vaginally delivered prescription drug candidate for endometriosis, positioned as the first treatment to preserve hormone balance and fertility ability, target pelvic cavity tissue via vaginal administration, rejuvenate ovarian tissue, and improve the telomere pathway in women with poor reproductive outcomes.
  • ELEGANT (TM) Portfolio Pioneering OTC product range of seven female sexual health products, including an Elegant Vaginal Moisturiser that treats vaginal atrophy through microbiome balancing; aimed at alleviating vaginal discharge, tackling vaginal infection without antibiotics via anti-adhesion strategies, and promoting optimal vaginal health. First OTC product planned for US launch.
  • Menopausal Hormone Therapy Products Range of low-dose female hormone therapies for hormone replacement treatment, delivered transdermally for systemic benefit and vaginally for localised symptoms. Formulated as an easy-to-use cosmetic-grade cream for daily use supporting healthier ageing.
  • Female Testosterone Replacement Therapy Patented female testosterone product delivered as a regular daily dose to combat Female Androgen Deficiency Syndrome (FADS), characterised by fatigue, disturbed sleep, low energy, motivation and self-esteem, and lack of sexual libido. Positioned as the first registered female testosterone product.
  • Male Testosterone Replacement Therapy Patient-acceptable transdermal testosterone cream suitable for use in chronic conditions, designed to contribute to the male hormone therapy market.
  • Vaginal Microbiome Products Products that help create and maintain a healthy vaginal environment by supporting a pH-balanced microbiome essential for a woman's sexual and reproductive lifecycle, particularly targeted at women preparing to conceive and maintain healthy pregnancies.
  • Vaginal Cannabinoids Research-stage therapies for chronic pelvic inflammatory diseases leveraging the high density of cannabinoid receptors in female pelvic organs, indicating strong propensity for cannabis absorption, treatment and efficacy.
  • Iron Supplementation Transdermal or buccal iron therapies for Iron Deficiency Anemia (IDA), offering easy iron absorption and avoidance of gastrointestinal issues that plague existing oral iron supplementation.

Quantifiable outcome

  • First treatment to preserve hormone balance and the ability to conceive for endometriosis patients
  • +5 more outcomes

Companies that use Viramal

Customer profile

Segments2 records

Ideal customer profiles2 records

Viramal technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Viramal partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • BigelcoreOthersViramal acquired Bigel, an established company, to develop their pioneering product portfolio of women's health therapies.

Recent moves7 records

Expansion highlights6 records

Viramal competitors and assessment

Company assessment

Direct peers

  • Theramex: Specialty pharmaceutical company exclusively dedicated to women's health, with portfolio spanning menopause, contraception, and reproductive medicine. Closely comparable as a women's health-only specialty pharma with similar therapeutic focus areas to Viramal's pipeline.
  • Evofem Biosciences: Women's health commercial-stage biopharmaceutical company with Phexxi vaginal gel for contraception and ongoing development in sexual health. Comparable focus on vaginal delivery formats and women's sexual/reproductive health commercialization.
  • TherapeuticsMD: Specialty pharmaceutical company focused exclusively on women's health, with marketed products in menopause hormone therapy and vaginal health. Direct overlap with Viramal's prescription and OTC women's health strategy, including similar focus on differentiated hormone delivery and vaginal health.
  • Myovant Sciences: Women's health pharma company developing therapies for uterine fibroids, endometriosis, and advanced prostate cancer. Directly comparable as a women's health-focused development-stage pharma with competing endometriosis asset (relugolix combination therapy), and was acquired by Sumitomo Pharma.
  • Daré Bioscience: Clinical-stage biopharmaceutical company focused on women's health with pipeline in contraception, vaginal health, and menopause. Comparable in stage and therapeutic focus, though Daré emphasizes contraceptive innovation and vaginal ring delivery rather than transdermal creams.
  • Agile Therapeutics: Women's health pharmaceutical company with FDA-approved Twirla contraceptive patch and pipeline in additional women's health indications. Comparable as a small-cap women's health pharma developing differentiated delivery formats for reproductive-age women.

Emerging players

  • ObsEva: Clinical-stage biopharmaceutical company developing therapies for women's reproductive health, with lead asset in preterm labor and pipeline in endometriosis. Comparable as a small women's health-focused development company, though currently facing significant financial distress.

Broad incumbents

  • Bayer (Women's Health): Global pharma with substantial women's health franchise including Mirena IUD, Yaz/Yasmin oral contraceptives, and hormone therapy products. Major incumbent with overlapping menopause, contraception, and reproductive health offerings and significant commercial scale.
  • Organon & Co. Global women's health-focused pharmaceutical company spun off from Merck in 2021, with established portfolio in contraception, fertility, menopause, and biosimilars. Broad incumbent with overlapping therapeutic areas including hormone therapy and reproductive health, serving as both competitor and potential acquirer.
  • AbbVie: Global pharmaceutical leader with major women's health franchise including Orilissa/Oriahnn for endometriosis and Lupron for reproductive conditions. Major incumbent competitor whose commercial infrastructure and payer relationships set the bar Viramal must clear to capture endometriosis market share.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Viramal social profiles

Digital presence

Viramal financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Viramal leadership team

Management profile

Number of profiles

Profiles9 records

Viramal subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Viramal funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Viramal M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Viramal

What does Viramal do?

Viramal is a specialty pharmaceutical company that develops prescription and over-the-counter treatments for women's sexual and reproductive health conditions, including endometriosis, menopause, female sexual health, fertility, and vaginal microbiome disorders. Products are formulated using the proprietary Fem Med Tech platform, which delivers active pharmaceutical ingredients through transdermal and vaginal cream formulations designed to increase potency, enable targeted tissue delivery, and minimise systemic side effects. The portfolio spans both clinical-stage prescription drug candidates and OTC consumer products such as the ELEGANT (TM) line.

Is Viramal a public or private company?

Viramal is a private company. It is classified as venture growth investor backed and is currently operating.

When was Viramal founded?

Viramal was founded in 2013. It employs 11 to 50 people.

Where is Viramal based?

Viramal is headquartered in London, United Kingdom, in the Europe region.

How does Viramal make money?

Three revenue lines are on record. Prescription Pharmaceutical Products are the primary driver. The others are over-the-Counter (OTC) Products and transdermal Hormone Therapies.

Who are Viramal's main competitors?

Direct peers on record are Theramex, Evofem Biosciences, TherapeuticsMD, Myovant Sciences, Daré Bioscience and Agile Therapeutics. ObsEva is listed as an emerging player. Broad incumbents are Bayer (Women's Health), Organon & Co. and AbbVie.

Does Viramal have an API?

No public API is recorded for Viramal.

What industry is Viramal in?

Viramal's product category is Women's Health Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health), with a secondary code of HLAIADAJ, Women’s Health (OTC Gynecologic). Its NAICS code is 325411 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales